John W. Newcomer, M.D., was awarded a $2.1 million contract to study the effectiveness of an injectable long-acting antipsychotic medication in individuals with schizophrenia.
The contract with Otsuka America Pharmaceutical Inc. will last two years. During that time, investigators from
FAU and collaborators that include faculty at the
Washington University in St. Louis School of Medicine will evaluate hospitalization rates and metabolic measurements during treatment with long-acting injectable aripiprazole, compared with daily oral antipsychotic treatment in the six months following an inpatient hospital stay related to schizophrenia.
"This research is important because the availability of second-generation long-acting antipsychotic medications offers an important tool to assist patients with medication adherence, which in turn may help lower health care costs and improve quality of life," said Newcomer.